Welcome To Burzynski Research Institute
Burzynski Research Institute (BRI), is a biopharmaceutical company committed to developing cancer treatments based on genomic and epigenomic principles. The goal of BRI is to develop and obtain approval of agents for the treatment of incurable types of cancer with an emphasis on malignant brain tumors. Research and developmental efforts are focused on Antineoplastons, a group of chemical substances found normally in urine and blood that are composed primarily of amino acids and peptides. Antineoplastons are now synthesized and have been evaluated in Phase II clinical trials. Plans are underway to study these agents in the Phase III setting.
Our research with Antineoplastons has been presented at a number of oncology and neuro-oncology meetings and appears in several peer-reviewed journals.
Below are FDA 483 inspection observations, as redacted by the FDA, which are based on recent inspections of our facilities and the corresponding responses to those FDA 483 observations.
BRI 483 redacted response.pdf